Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy
- 31 August 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Immunotherapy
- Vol. 9 (11), 913-927
- https://doi.org/10.2217/imt-2017-0052
Abstract
Spurred by the survival benefits seen with the use of checkpoint blockade in non-small-cell lung cancer (NSCLC), there has been a growing interest in the potential applications of immunotherapy. Despite this, the objective response rate for single-agent immunotherapy remains <= 20% in patients with advanced NSCLC. A combinatorial approach that utilizes both chemotherapy and immunotherapy is a potential strategy to increase antitumor efficacy. Accumulating evidence has shown that the immunomodulatory effects of chemotherapeutic agents can be exploited in a combinational approach. Herein, we review the influence of specific chemotherapeutic agents on the tumor immune microenvironment in preclinical and clinical studies, and establish the rationale for combination chemoimmunotherapy for the treatment of NSCLC.This publication has 86 references indexed in Scilit:
- Update on taxane development: new analogs and new formulationsDrug Design, Development and Therapy, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent mannerJournal of Immunotoxicology, 2012
- Prognostic Immune Markers in Non–Small Cell Lung CancerClinical Cancer Research, 2011
- Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responsesCancer Immunology, Immunotherapy, 2011
- Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant MesotheliomaThe Journal of Immunology, 2010
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceJCI Insight, 2010
- Differential effects of Paclitaxel on dendritic cell functionBMC Immunology, 2010
- Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer GrowthClinical Cancer Research, 2007